Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Cyclophosphamide in CTD-ILD
NCT01862926Phase 3Completed
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Nov 2014
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in interstitial lung disease (ILD) (2 arms), sponsored by Royal Brompton and Harefield hospitals. Primary endpoint: Absolute change in Forced Vital Capacity at 48 weeks. Started Nov 2014; status: completed.
02
Drugs
rituximab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT01862926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862926.